We are monitoring the impact of COVID-19 on Antibiotics Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2020
ID: 10117
Share on
Share on

Global Antibiotics Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report – Segmented By Action Mechanism, Drug Class and Region (North America, Europe, Asia pacific, Latin America, Middle East and Africa) – Industry Forecast (2020 to 2025)

Pulished: September, 2020
ID: 10117
Pages: 160

Antibiotics Market Size (2020 to 2025)

As per our research analysis report, the global antibiotics market size is expected to reach USD 57.4 billion by 2025, hiking at a 4.0% CAGR from 2020 to 2025.

Antibodies are meds that battle bacterial diseases in individuals and animals. They work by defeating the microscopic organisms or making it difficult for them to develop and duplicate. Before microorganisms can increase and cause indications, the invulnerable framework can regularly defeat them. White platelets (WBCs) attack damaging microbes and, regardless of whether symptoms do happen, the immune system can typically adapt and ward off the disease. In some cases, anyhow, the quantity of hurtful microorganisms is extreme, and the resistant framework can't battle them all. Antibodies are helpful in this situation. A few present-day anti-infection agents are accessible, and they are typically just accessible with a remedy in many nations: orally (by mouth) could be pills, cases, or fluids. Topically may be a cream, shower, or balm that you put on your skin. It could likewise be eye or ear drops through an infusion or intravenously (I.V) for the most part for more genuine contaminations. Antibodies treat certain bacterial diseases, like strep throat, urinary tract contaminations, and E. coli.

Just bacterial diseases can be killed with antibody agents. Infections completely bring about the normal cold, influenza, most coughs, some bronchitis diseases, most irritated throats, and stomach influenza. Antibodies agents do not attempt to treat them. Since the gut is full of microbes - both great and terrible - antibodies regularly influence the stomach-related framework while they're treating a disease. Regular results incorporate Vomiting, Nausea, Diarrhoea, Bloating or heartburn, Abdominal torment, and Loss of hunger. There are several ways to classify antibiotics, but the most common classification is based on their chemical composition, range of function, and mode of action. Currently, the market for beta-lactam and beta-lactamase antibiotic inhibitors is strong among healthcare providers.

MARKET DRIVERS:

Y-O-Y growth in the incidence of infectious diseases and increasing support from the governments drive the global antibiotics market growth.

Generic versions are launched to the market to deliver cost-effective medicines and increase the reach of these drugs to citizens of all economic backgrounds. Generic copies are popular because of their popularity and affordability. For example, the average brand name drug price was almost 4 times the average generic price, according to a report published on the National Institute of Technology (NPI). Besides, businesses are now working on producing generic versions to deliver antibiotics at a reduced cost. Also, support from government officials is expected to improve the development of generic antibiotics, which will ultimately fuel the growth rate of the global antibiotics market.

Increased investment from producers for the production of new medicines drives the worldwide demand for antibiotics for antibiotics. However, the unruly and sustained application of antibiotics in the last few decades has contributed to the growth of antibiotic-resistant bacteria and pathogens. Infections such as measles, pneumonia, and gonorrhea, which were originally susceptible to antibiotics, were resistant to these medications. However, the antibiotics industry is projected to see substantial growth due to the discovery of innovative molecules and new hybrid therapies to treat antibiotic-resistant microbial infections. Advances in antibiotic medications and new hybrid treatments for the treatment of antibiotic-resistant microbial infections are driving the development. For this, a special classification by the regulatory authority of multiple prospective pharmaceutical firms is one of the reasons projected to fuel the global antibiotics market growth.

Collaborations on the development of antibiotics are projected to contribute to developing a high number of antibiotic drugs. The acquisition and cooperation of various producers driving the global demand in drugs for antibiotics. The growing number of public-private partnerships in which public bodies offer financing and creative R&D approaches to antibiotic-developing companies is expected to improve the product pipeline. Growing the prevalence of chronic and infectious diseases worldwide and improving the effectiveness of antibiotics that can cure a wide range of bacterial infections such as pneumonia, malaria, and tuberculosis, and the gap in the demand and supply of antibiotics are the other factors that have contributed to the exponential growth of the antibiotics industry.

MARKET RESTRAINTS:

Strict regulatory rules for the acceptance of new products on the market are pressuring the antibiotics market. The side effects triggered by the use of antibiotic drugs and the lack of knowledge among people about the use of antibiotic drugs are factors that impede the growth of the antibiotics market. Nonetheless, continuing clinical trials are being performed by a variety of pharmaceutical firms and would increase the demand for antibiotics in the future.

COVID-19 Impact on the global antibiotics market:

COVID-19 affects individuals of all ages, most of whom experience mild to severe symptoms. The epidemic is increasing increasingly worldwide, and the rate of deaths is high. Antimicrobial care for patients with SARS-CoV-2 infection is rare. While antimicrobials used have been documented in research, there is inadequate consideration of their value or the risk that they may be used indiscriminately or incorrectly, particularly when broad-spectrum antibiotics are used in combination. Still, the spread of COVID-19 across the globe was followed by an improvement in antibiotics use.

The results are focused on estimates that up to 95 % of COVID-19 patients are prescribed antibiotics as part of their care and fear that such large-scale opioid use may have larger environmental consequences. However, following the start of the COVID-19 pandemic, there has been increasing worry about the possible rise in AMR secondary to expanded antibiotic prescribing in COVID-19 patients. Other antibiotics also suggested for the treatment of COVID-19 include azithromycin, quercetin, rapamycin, and doxycycline. However, the combination of hydroxychloroquine (a chloroquine derivative considered an ancient antimalarial drug) and azithromycin proved to be much more successful in the treatment of COVID-19. Azithromycin also prevents the replication of other viruses such as Zika and Zika. Azithromycin, doxycycline, and rapamycin are antibiotic medications that block protein synthesis and reduce inflammation and viral replication.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

Based on action metabolism, drug call, and region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global antibiotics market has been segmented and sub-segmented into the following categories:

Antibiotics Market – By Action Mechanism:

  • Cell Wall Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Rna Synthesis Inhibitors
  • Mycolic Acid Synthesis Inhibitors
  • Folic Acid Synthesis Inhibitors

The drugs prevent the bacteria from synthesizing a molecule in the cell wall called peptidoglycan, which provides the cell wall with the strength it needs to survive in the human body. These types of drugs are expected to grow at the fastest rate, among others.

Many antibiotic drugs work to inhibit DNA synthesis and also inhibit the transformation of DNA into RNA. It is a significant discovery as it can help cure many naturals borne diseases that we could not cure. These types of drugs have the second-largest share.

The drugs shown to inhibit mycolic acid biosynthesis are isoniazid and triclosan. Besides, pyrazinamide was shown to inhibit fatty acid synthase type I, which, in turn, provides precursors for fatty acid elongation to long-chain mycolic acids by fatty acid synthase II. Essential for viability and virulence, enzymes involved in mycolic acid biosynthesis represent novel targets for drug development.

Folic acid helps the body to maintain and produce new cells. Many antibiotics are now in the market, inhibiting folic acid synthesis and reducing excessive cell generation. Due to fewer known diseases of these kinds, the drugs have the lowest market share right now but soon can overtake others as we progress in identifying new diseases.

Antibiotics Market – By Drug Class:

  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • Others

The other antibiotics segment includes tetracyclines, imidazoles, lincosamides, and monoclonal antibodies and is projected to grow at the highest CAGR from 2020 to 2025. The development of monoclonal antibodies for individuals that have developed antibiotic-resistance is a key highlight of this segment. Penicillin is the oldest drug to be discovered and still holds a significant share in the market. The cephalosporins have the largest market share ahead of penicillin. Increasing incidence of pneumonia, bloodstream infections, and Urinary Tract Infections (UTI) is anticipated to foster the usage of carbapenems class of antibiotics.

Antibiotics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America has the second-largest share in the global antibiotics market. It is because of massive expenditure from the US fed on Research and Development in the antibiotics market.

The European region is in third place in occupying a leading share in the global antibiotics market. European countries have the best medical facilities worldwide, so a large amount is spent developing new antibiotics drugs. Europe region firms are increasing their production to cater to the world's needs. With their consistency and efficiency of drugs, the European region can be seen as a market leader in the future.

The Asia Pacific is the global antibiotics market leader as they have extensive production facilities in countries like India. The ability to produce drugs in large quantities drives the antibiotics market's growth, and the Asia Pacific will remain the leader during the forecasting period. The need to cater to large populations can make the companies self-sustained in the market, giving room for other companies in other countries.

KEY MARKET PARTICIPANTS:

Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG some of the promising companies in the global antibiotics market.

Antibiotics are becoming critical for human and animal life. Due to several causes, the antibiotics market has seen endless growth and opportunities. In this pandemic, some of these antibiotics are used in human and animal medicine and are regarded as critically important. There has been a greater than average level of antibiotic administration in a pandemic as it is important to save the lives of COVID-19 patients, even though this requires the use of antimicrobials to treat or avoid complications and secondary infections.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. OVERVIEW
    1. Executive Summary
    2. Key Inferences
  4. DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. MARKET SEGMENTATION
    1. By Action Mechanism
      1. Cell Wall Synthesis Inhibitors
      2. Dna Synthesis Inhibitors
      3. Rna Synthesis Inhibitors
      4. Mycolic Acid Synthesis Inhibitors
      5. Folic Acid Synthesis Inhibitors
      6. Y-o-Y Growth Analysis, By Action Mechanism
      7. Market Attractiveness Analysis, By Action Mechanism
      8. Market Share Analysis, By Action Mechanism
    2. By Drug Class
      1. Cephalosporins
      2. Penicillins
      3. Fluoroquinolones
      4. Macrolides
      5. Carbapenems
      6. Aminoglycosides
      7. Sulfonamides
      8. Others
      9. Y-o-Y Growth Analysis, By Drug Class
      10. Market Attractiveness Analysis, By Drug Class
      11. Market Share Analysis, By Drug Class
  6. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. North America
      1. Introduction
      2. United States
      3. Canada
    3. Europe
      1. Introduction
      2. U.K
      3. Spain
      4. Germany
      5. Italy
      6. France
      7. Rest of Europe
    4. Asia-Pacific
      1. Introduction
      2. China
      3. India
      4. Japan
      5. South Korea
      6. Australia and NZ
      7. Rest of APAC
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
      5. Rest of Latin America
    6. Middle East & Africa
      1. Introduction
      2. Middle-East
      3. Africa
  7. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. MARKET LEADERS' ANALYSIS
    1. Glaxosmithkline
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Johnson and Johnson
    3. Pfizer PLC
    4. Bayer AG
    5. Novartis AG
    6. Abbott Inc.
    7. Merck & Co. Inc.
    8. Sanofi SA
    9. F. Hoffmann-La Roche AG
  9. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  11. APPENDIX
    1. List of Tables
    2. List of Figures
  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of By Diagnostic Wearable Devices, and Therapeutic Wearable Devices along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Antibiotics Market, By Region, From 2020 to 2025 (USD Billion)
  2. Global Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  3. Global Cell Wall Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  4. Global DNA Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  5. Global Rna Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  6. Global Mycolic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  7. Global Folic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  8. Global Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  9. Global Cephalosporins Market, By Region, From 2020 to 2025 (USD Billion)
  10. Global Penicillins Market, By Region, From 2020 to 2025 (USD Billion)
  11. Global Fluoroquinolones Market, By Region, From 2020 to 2025 (USD Billion)
  12. Global Macrolides Market, By Region, From 2020 to 2025 (USD Billion)
  13. Global Carbapenems Market, By Region, From 2020 to 2025 (USD Billion)
  14. Global Aminoglycosides Market, By Region, From 2020 to 2025 (USD Billion)
  15. Global Sulfonamides Market, By Region, From 2020 to 2025 (USD Billion)
  16. North America Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  17. North America Cell Wall Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  18. North America DNA Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  19. North America Rna Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  20. North America Mycolic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  21. North America Folic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  22. North America Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  23. North America Cephalosporins Market, By Region, From 2020 to 2025 (USD Billion)
  24. North America Penicillins Market, By Region, From 2020 to 2025 (USD Billion)
  25. North America Fluoroquinolones Market, By Region, From 2020 to 2025 (USD Billion)
  26. North America Macrolides Market, By Region, From 2020 to 2025 (USD Billion)
  27. North America Carbapenems Market, By Region, From 2020 to 2025 (USD Billion)
  28. North America Aminoglycosides Market, By Region, From 2020 to 2025 (USD Billion)
  29. North America Sulfonamides Market, By Region, From 2020 to 2025 (USD Billion)
  30. United States Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  31. United States Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  32. Canada Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  33. Canada Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  34. Europe Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  35. Europe Cell Wall Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  36. Europe DNA Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  37. Europe Rna Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  38. Europe Mycolic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  39. Europe Folic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  40. Europe Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  41. Europe Cephalosporins Market, By Region, From 2020 to 2025 (USD Billion)
  42. Europe Penicillins Market, By Region, From 2020 to 2025 (USD Billion)
  43. Europe Fluoroquinolones Market, By Region, From 2020 to 2025 (USD Billion)
  44. Europe Macrolides Market, By Region, From 2020 to 2025 (USD Billion)
  45. Europe Carbapenems Market, By Region, From 2020 to 2025 (USD Billion)
  46. Europe Aminoglycosides Market, By Region, From 2020 to 2025 (USD Billion)
  47. Europe Sulfonamides Market, By Region, From 2020 to 2025 (USD Billion)
  48. U.K. Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  49. U.K. Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  50. Germany Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  51. Germany Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  52. France Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  53. France Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  54. Italy Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  55. Italy Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  56. Spain Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  57. Spain Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  58. Asia Pacific Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  59. Asia Pacific Cell Wall Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  60. Asia Pacific DNA Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  61. Asia Pacific Rna Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  62. Asia Pacific Mycolic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  63. Asia Pacific Folic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  64. Asia Pacific Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  65. Asia Pacific Cephalosporins Market, By Region, From 2020 to 2025 (USD Billion)
  66. Asia Pacific Penicillins Market, By Region, From 2020 to 2025 (USD Billion)
  67. Asia Pacific Fluoroquinolones Market, By Region, From 2020 to 2025 (USD Billion)
  68. Asia Pacific Macrolides Market, By Region, From 2020 to 2025 (USD Billion)
  69. Asia Pacific Carbapenems Market, By Region, From 2020 to 2025 (USD Billion)
  70. Asia Pacific Aminoglycosides Market, By Region, From 2020 to 2025 (USD Billion)
  71. Asia Pacific Sulfonamides Market, By Region, From 2020 to 2025 (USD Billion)
  72. Japan Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  73. Japan Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  74. China Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  75. China Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  76. India Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  77. India Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  78. Australia Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  79. Australia Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  80. South Korea Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  81. South Korea Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  82. Latin America Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  83. Latin America Cell Wall Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  84. Latin America DNA Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  85. Latin America Rna Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  86. Latin America Mycolic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  87. Latin America Folic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  88. Latin America Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  89. Latin America Cephalosporins Market, By Region, From 2020 to 2025 (USD Billion)
  90. Latin America Penicillins Market, By Region, From 2020 to 2025 (USD Billion)
  91. Latin America Fluoroquinolones Market, By Region, From 2020 to 2025 (USD Billion)
  92. Latin America Macrolides Market, By Region, From 2020 to 2025 (USD Billion)
  93. Latin America Carbapenems Market, By Region, From 2020 to 2025 (USD Billion)
  94. Latin America Aminoglycosides Market, By Region, From 2020 to 2025 (USD Billion)
  95. Latin America Sulfonamides Market, By Region, From 2020 to 2025 (USD Billion)
  96. Brazil Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  97. Brazil Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  98. Argentina Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  99. Argentina Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  100. Mexico Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  101. Mexico Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  102. Rest of Latin America Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  103. Rest of Latin America Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  104. Middle East and Africa Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  105. Middle East and Africa Cell Wall Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  106. Middle East and Africa DNA Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  107. Middle East and Africa Rna Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  108. Middle East and Africa Mycolic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  109. Middle East and Africa Folic Acid Synthesis Inhibitors Market, By Region, From 2020 to 2025 (USD Billion)
  110. Middle East and Africa Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  111. Middle East and Africa Cephalosporins Market, By Region, From 2020 to 2025 (USD Billion)
  112. Middle East and Africa Penicillins Market, By Region, From 2020 to 2025 (USD Billion)
  113. Middle East and Africa Fluoroquinolones Market, By Region, From 2020 to 2025 (USD Billion)
  114. Middle East and Africa Macrolides Market, By Region, From 2020 to 2025 (USD Billion)
  115. Middle East and Africa Carbapenems Market, By Region, From 2020 to 2025 (USD Billion)
  116. Middle East and Africa Aminoglycosides Market, By Region, From 2020 to 2025 (USD Billion)
  117. Middle East and Africa Sulfonamides Market, By Region, From 2020 to 2025 (USD Billion)
  118. Middle East Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  119. Middle East Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)
  120. Africa Antibiotics Market, By Action Mechanism, From 2020 to 2025 (USD Billion)
  121. Africa Antibiotics Market, By Drug Class, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample